Data completeness
0/8 — Limited
Drug data last refreshed 43m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POVAN (pyrvinium pamoate) is an oral suspension anthelmintic agent indicated for parasitic infections, primarily pinworm (Enterobius vermicularis). The drug works by disrupting mitochondrial function in parasites, leading to their paralysis and expulsion.
Pre-Launch
Early-stage product requiring cross-functional launch infrastructure; small to moderate commercial footprint expected for niche parasitic indication.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
POVAN represents a pre-launch opportunity with modest career growth potential in a niche parasitic disease market. Working on this product offers exposure to pediatric formulation strategy and launch execution, but limited long-term scale compared to larger therapeutic areas.
Brand ManagerLaunch Manager
Worked on POVAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.